PubMed:22808010
Annnotations
LitCoin-entities-OrganismTaxon-PD
{"project":"LitCoin-entities-OrganismTaxon-PD","denotations":[{"id":"T1","span":{"begin":1315,"end":1321},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"NCBItxid:12939"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin-sentences
{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":149},"obj":"Sentence"},{"id":"T2","span":{"begin":150,"end":240},"obj":"Sentence"},{"id":"T3","span":{"begin":241,"end":482},"obj":"Sentence"},{"id":"T4","span":{"begin":483,"end":662},"obj":"Sentence"},{"id":"T5","span":{"begin":663,"end":748},"obj":"Sentence"},{"id":"T6","span":{"begin":749,"end":855},"obj":"Sentence"},{"id":"T7","span":{"begin":856,"end":968},"obj":"Sentence"},{"id":"T8","span":{"begin":969,"end":1046},"obj":"Sentence"},{"id":"T9","span":{"begin":1047,"end":1168},"obj":"Sentence"},{"id":"T10","span":{"begin":1169,"end":1323},"obj":"Sentence"},{"id":"T11","span":{"begin":1324,"end":1409},"obj":"Sentence"},{"id":"T12","span":{"begin":1410,"end":1542},"obj":"Sentence"},{"id":"T13","span":{"begin":1543,"end":1712},"obj":"Sentence"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin-entities
{"project":"LitCoin-entities","denotations":[{"id":"9020","span":{"begin":12,"end":16},"obj":"GeneOrGeneProduct"},{"id":"9021","span":{"begin":77,"end":87},"obj":"GeneOrGeneProduct"},{"id":"9022","span":{"begin":111,"end":114},"obj":"GeneOrGeneProduct"},{"id":"9023","span":{"begin":178,"end":181},"obj":"GeneOrGeneProduct"},{"id":"9024","span":{"begin":182,"end":186},"obj":"GeneOrGeneProduct"},{"id":"9025","span":{"begin":241,"end":246},"obj":"GeneOrGeneProduct"},{"id":"9026","span":{"begin":334,"end":338},"obj":"GeneOrGeneProduct"},{"id":"9027","span":{"begin":365,"end":373},"obj":"GeneOrGeneProduct"},{"id":"9028","span":{"begin":411,"end":423},"obj":"DiseaseOrPhenotypicFeature"},{"id":"9029","span":{"begin":429,"end":433},"obj":"GeneOrGeneProduct"},{"id":"9030","span":{"begin":501,"end":504},"obj":"GeneOrGeneProduct"},{"id":"9031","span":{"begin":505,"end":509},"obj":"GeneOrGeneProduct"},{"id":"9032","span":{"begin":592,"end":595},"obj":"GeneOrGeneProduct"},{"id":"9033","span":{"begin":596,"end":600},"obj":"GeneOrGeneProduct"},{"id":"9034","span":{"begin":676,"end":679},"obj":"GeneOrGeneProduct"},{"id":"9035","span":{"begin":680,"end":684},"obj":"GeneOrGeneProduct"},{"id":"9036","span":{"begin":765,"end":768},"obj":"GeneOrGeneProduct"},{"id":"9037","span":{"begin":805,"end":809},"obj":"GeneOrGeneProduct"},{"id":"9038","span":{"begin":811,"end":815},"obj":"GeneOrGeneProduct"},{"id":"9039","span":{"begin":817,"end":821},"obj":"GeneOrGeneProduct"},{"id":"9040","span":{"begin":823,"end":827},"obj":"GeneOrGeneProduct"},{"id":"9041","span":{"begin":829,"end":832},"obj":"GeneOrGeneProduct"},{"id":"9042","span":{"begin":834,"end":839},"obj":"GeneOrGeneProduct"},{"id":"9043","span":{"begin":844,"end":854},"obj":"GeneOrGeneProduct"},{"id":"9044","span":{"begin":856,"end":859},"obj":"GeneOrGeneProduct"},{"id":"9045","span":{"begin":860,"end":864},"obj":"GeneOrGeneProduct"},{"id":"9046","span":{"begin":905,"end":911},"obj":"GeneOrGeneProduct"},{"id":"9047","span":{"begin":913,"end":917},"obj":"GeneOrGeneProduct"},{"id":"9048","span":{"begin":919,"end":928},"obj":"GeneOrGeneProduct"},{"id":"9049","span":{"begin":930,"end":938},"obj":"GeneOrGeneProduct"},{"id":"9050","span":{"begin":940,"end":949},"obj":"GeneOrGeneProduct"},{"id":"9051","span":{"begin":954,"end":967},"obj":"GeneOrGeneProduct"},{"id":"9052","span":{"begin":969,"end":972},"obj":"GeneOrGeneProduct"},{"id":"9053","span":{"begin":1069,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"9054","span":{"begin":1080,"end":1085},"obj":"GeneOrGeneProduct"},{"id":"9055","span":{"begin":1095,"end":1101},"obj":"GeneOrGeneProduct"},{"id":"9056","span":{"begin":1103,"end":1109},"obj":"GeneOrGeneProduct"},{"id":"9057","span":{"begin":1114,"end":1118},"obj":"GeneOrGeneProduct"},{"id":"9058","span":{"begin":1124,"end":1127},"obj":"GeneOrGeneProduct"},{"id":"9059","span":{"begin":1169,"end":1174},"obj":"GeneOrGeneProduct"},{"id":"9060","span":{"begin":1237,"end":1241},"obj":"GeneOrGeneProduct"},{"id":"9061","span":{"begin":1242,"end":1246},"obj":"GeneOrGeneProduct"},{"id":"9062","span":{"begin":1247,"end":1252},"obj":"GeneOrGeneProduct"},{"id":"9063","span":{"begin":1315,"end":1321},"obj":"DiseaseOrPhenotypicFeature"},{"id":"9064","span":{"begin":1353,"end":1365},"obj":"GeneOrGeneProduct"},{"id":"9065","span":{"begin":1366,"end":1376},"obj":"GeneOrGeneProduct"},{"id":"9066","span":{"begin":1405,"end":1408},"obj":"GeneOrGeneProduct"},{"id":"9067","span":{"begin":1424,"end":1434},"obj":"GeneOrGeneProduct"},{"id":"9068","span":{"begin":1547,"end":1551},"obj":"GeneOrGeneProduct"},{"id":"9069","span":{"begin":1631,"end":1641},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A48","pred":"db_id","subj":"9067","obj":"NCBIGene:72049"},{"id":"A13","pred":"db_id","subj":"9032","obj":"NCBIGene:13856"},{"id":"A39","pred":"db_id","subj":"9058","obj":"NCBIGene:13856"},{"id":"A10","pred":"db_id","subj":"9029","obj":"NCBIGene:26417"},{"id":"A14","pred":"db_id","subj":"9033","obj":"NCBIGene:13857"},{"id":"A24","pred":"db_id","subj":"9043","obj":"NCBIGene:20715"},{"id":"A23","pred":"db_id","subj":"9042","obj":"NCBIGene:228775"},{"id":"A41","pred":"db_id","subj":"9060","obj":"NCBIGene:13857"},{"id":"A45","pred":"db_id","subj":"9064","obj":"NCBIGene:72049"},{"id":"A29","pred":"db_id","subj":"9048","obj":"NCBIGene:12444"},{"id":"A50","pred":"db_id","subj":"9069","obj":"NCBIGene:72049"},{"id":"A15","pred":"db_id","subj":"9034","obj":"NCBIGene:13856"},{"id":"A36","pred":"db_id","subj":"9055","obj":"NCBIGene:114716"},{"id":"A6","pred":"db_id","subj":"9025","obj":"NCBIGene:12048"},{"id":"A21","pred":"db_id","subj":"9040","obj":"NCBIGene:18712"},{"id":"A49","pred":"db_id","subj":"9068","obj":"NCBIGene:13857"},{"id":"A43","pred":"db_id","subj":"9062","obj":"NCBIGene:20850"},{"id":"A2","pred":"db_id","subj":"9021","obj":"NCBIGene:72049"},{"id":"A7","pred":"db_id","subj":"9026","obj":"NCBIGene:13857"},{"id":"A20","pred":"db_id","subj":"9039","obj":"NCBIGene:223775"},{"id":"A35","pred":"db_id","subj":"9054","obj":"NCBIGene:216233"},{"id":"A34","pred":"db_id","subj":"9053","obj":"NCBIGene:12702"},{"id":"A9","pred":"db_id","subj":"9028","obj":"MESH:D011086"},{"id":"A22","pred":"db_id","subj":"9041","obj":"NCBIGene:12125"},{"id":"A33","pred":"db_id","subj":"9052","obj":"NCBIGene:13856"},{"id":"A11","pred":"db_id","subj":"9030","obj":"NCBIGene:13856"},{"id":"A18","pred":"db_id","subj":"9037","obj":"NCBIGene:17095"},{"id":"A8","pred":"db_id","subj":"9027","obj":"NCBIGene:18708"},{"id":"A5","pred":"db_id","subj":"9024","obj":"NCBIGene:13857"},{"id":"A3","pred":"db_id","subj":"9022","obj":"NCBIGene:13856"},{"id":"A46","pred":"db_id","subj":"9065","obj":"NCBIGene:72049"},{"id":"A12","pred":"db_id","subj":"9031","obj":"NCBIGene:13857"},{"id":"A28","pred":"db_id","subj":"9047","obj":"NCBIGene:12228"},{"id":"A25","pred":"db_id","subj":"9044","obj":"NCBIGene:13856"},{"id":"A30","pred":"db_id","subj":"9049","obj":"NCBIGene:12576"},{"id":"A37","pred":"db_id","subj":"9056","obj":"NCBIGene:114715"},{"id":"A40","pred":"db_id","subj":"9059","obj":"NCBIGene:216233"},{"id":"A17","pred":"db_id","subj":"9036","obj":"NCBIGene:13856"},{"id":"A4","pred":"db_id","subj":"9023","obj":"NCBIGene:13856"},{"id":"A19","pred":"db_id","subj":"9038","obj":"NCBIGene:14455"},{"id":"A32","pred":"db_id","subj":"9051","obj":"NCBIGene:239083"},{"id":"A31","pred":"db_id","subj":"9050","obj":"NCBIGene:12452"},{"id":"A42","pred":"db_id","subj":"9061","obj":"NCBIGene:16452"},{"id":"A26","pred":"db_id","subj":"9045","obj":"NCBIGene:13857"},{"id":"A27","pred":"db_id","subj":"9046","obj":"NCBIGene:12530"},{"id":"A1","pred":"db_id","subj":"9020","obj":"NCBIGene:13857"},{"id":"A16","pred":"db_id","subj":"9035","obj":"NCBIGene:13857"},{"id":"A38","pred":"db_id","subj":"9057","obj":"NCBIGene:74427"},{"id":"A47","pred":"db_id","subj":"9066","obj":"NCBIGene:13856"},{"id":"A44","pred":"db_id","subj":"9063","obj":"MESH:D000740"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin_Mondo
{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":411,"end":423},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":1315,"end":1321},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0005571"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0002280"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin-GeneOrGeneProduct-v0
{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T1","span":{"begin":12,"end":16},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":18,"end":27},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":77,"end":87},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":93,"end":98},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":99,"end":107},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":139,"end":148},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":158,"end":166},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":182,"end":186},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":194,"end":199},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":241,"end":246},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":267,"end":278},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":324,"end":333},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":334,"end":338},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":352,"end":356},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":359,"end":364},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":369,"end":373},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":429,"end":433},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":434,"end":444},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":495,"end":500},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":505,"end":509},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":596,"end":600},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":620,"end":624},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":645,"end":649},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":680,"end":684},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":692,"end":703},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":743,"end":747},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":769,"end":778},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":779,"end":795},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":805,"end":809},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":811,"end":815},"obj":"GeneOrGeneProduct"},{"id":"T31","span":{"begin":817,"end":821},"obj":"GeneOrGeneProduct"},{"id":"T32","span":{"begin":823,"end":827},"obj":"GeneOrGeneProduct"},{"id":"T33","span":{"begin":834,"end":839},"obj":"GeneOrGeneProduct"},{"id":"T34","span":{"begin":844,"end":854},"obj":"GeneOrGeneProduct"},{"id":"T35","span":{"begin":860,"end":864},"obj":"GeneOrGeneProduct"},{"id":"T36","span":{"begin":875,"end":885},"obj":"GeneOrGeneProduct"},{"id":"T37","span":{"begin":886,"end":895},"obj":"GeneOrGeneProduct"},{"id":"T38","span":{"begin":905,"end":911},"obj":"GeneOrGeneProduct"},{"id":"T39","span":{"begin":913,"end":917},"obj":"GeneOrGeneProduct"},{"id":"T40","span":{"begin":919,"end":925},"obj":"GeneOrGeneProduct"},{"id":"T41","span":{"begin":926,"end":928},"obj":"GeneOrGeneProduct"},{"id":"T42","span":{"begin":934,"end":938},"obj":"GeneOrGeneProduct"},{"id":"T43","span":{"begin":940,"end":946},"obj":"GeneOrGeneProduct"},{"id":"T44","span":{"begin":954,"end":962},"obj":"GeneOrGeneProduct"},{"id":"T45","span":{"begin":963,"end":967},"obj":"GeneOrGeneProduct"},{"id":"T46","span":{"begin":973,"end":983},"obj":"GeneOrGeneProduct"},{"id":"T47","span":{"begin":987,"end":1006},"obj":"GeneOrGeneProduct"},{"id":"T48","span":{"begin":1007,"end":1014},"obj":"GeneOrGeneProduct"},{"id":"T49","span":{"begin":1069,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T50","span":{"begin":1080,"end":1085},"obj":"GeneOrGeneProduct"},{"id":"T51","span":{"begin":1095,"end":1101},"obj":"GeneOrGeneProduct"},{"id":"T52","span":{"begin":1103,"end":1109},"obj":"GeneOrGeneProduct"},{"id":"T53","span":{"begin":1114,"end":1118},"obj":"GeneOrGeneProduct"},{"id":"T54","span":{"begin":1128,"end":1135},"obj":"GeneOrGeneProduct"},{"id":"T55","span":{"begin":1169,"end":1174},"obj":"GeneOrGeneProduct"},{"id":"T56","span":{"begin":1237,"end":1241},"obj":"GeneOrGeneProduct"},{"id":"T57","span":{"begin":1242,"end":1246},"obj":"GeneOrGeneProduct"},{"id":"T58","span":{"begin":1247,"end":1252},"obj":"GeneOrGeneProduct"},{"id":"T59","span":{"begin":1330,"end":1339},"obj":"GeneOrGeneProduct"},{"id":"T60","span":{"begin":1344,"end":1352},"obj":"GeneOrGeneProduct"},{"id":"T61","span":{"begin":1357,"end":1365},"obj":"GeneOrGeneProduct"},{"id":"T62","span":{"begin":1366,"end":1376},"obj":"GeneOrGeneProduct"},{"id":"T63","span":{"begin":1397,"end":1401},"obj":"GeneOrGeneProduct"},{"id":"T64","span":{"begin":1424,"end":1434},"obj":"GeneOrGeneProduct"},{"id":"T65","span":{"begin":1532,"end":1541},"obj":"GeneOrGeneProduct"},{"id":"T66","span":{"begin":1547,"end":1551},"obj":"GeneOrGeneProduct"},{"id":"T67","span":{"begin":1631,"end":1641},"obj":"GeneOrGeneProduct"},{"id":"T68","span":{"begin":1658,"end":1663},"obj":"GeneOrGeneProduct"},{"id":"T69","span":{"begin":1673,"end":1682},"obj":"GeneOrGeneProduct"},{"id":"T70","span":{"begin":1702,"end":1711},"obj":"GeneOrGeneProduct"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin-GeneOrGeneProduct-v2
{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T1","span":{"begin":12,"end":16},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":77,"end":87},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":93,"end":98},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":99,"end":107},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":182,"end":186},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":241,"end":246},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":324,"end":333},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":334,"end":338},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":352,"end":356},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":359,"end":364},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":369,"end":373},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":429,"end":433},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":495,"end":500},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":505,"end":509},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":596,"end":600},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":645,"end":649},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":680,"end":684},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":743,"end":747},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":779,"end":795},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":805,"end":809},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":811,"end":815},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":817,"end":821},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":823,"end":827},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":834,"end":839},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":844,"end":854},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":860,"end":864},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":875,"end":885},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":905,"end":911},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":913,"end":917},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":919,"end":925},"obj":"GeneOrGeneProduct"},{"id":"T31","span":{"begin":934,"end":938},"obj":"GeneOrGeneProduct"},{"id":"T32","span":{"begin":940,"end":946},"obj":"GeneOrGeneProduct"},{"id":"T33","span":{"begin":954,"end":962},"obj":"GeneOrGeneProduct"},{"id":"T34","span":{"begin":987,"end":1006},"obj":"GeneOrGeneProduct"},{"id":"T35","span":{"begin":1069,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T36","span":{"begin":1080,"end":1085},"obj":"GeneOrGeneProduct"},{"id":"T37","span":{"begin":1095,"end":1101},"obj":"GeneOrGeneProduct"},{"id":"T38","span":{"begin":1103,"end":1109},"obj":"GeneOrGeneProduct"},{"id":"T39","span":{"begin":1114,"end":1118},"obj":"GeneOrGeneProduct"},{"id":"T40","span":{"begin":1169,"end":1174},"obj":"GeneOrGeneProduct"},{"id":"T41","span":{"begin":1237,"end":1241},"obj":"GeneOrGeneProduct"},{"id":"T42","span":{"begin":1242,"end":1246},"obj":"GeneOrGeneProduct"},{"id":"T43","span":{"begin":1247,"end":1252},"obj":"GeneOrGeneProduct"},{"id":"T44","span":{"begin":1344,"end":1352},"obj":"GeneOrGeneProduct"},{"id":"T45","span":{"begin":1357,"end":1365},"obj":"GeneOrGeneProduct"},{"id":"T46","span":{"begin":1366,"end":1376},"obj":"GeneOrGeneProduct"},{"id":"T47","span":{"begin":1397,"end":1401},"obj":"GeneOrGeneProduct"},{"id":"T48","span":{"begin":1424,"end":1434},"obj":"GeneOrGeneProduct"},{"id":"T49","span":{"begin":1547,"end":1551},"obj":"GeneOrGeneProduct"},{"id":"T50","span":{"begin":1631,"end":1641},"obj":"GeneOrGeneProduct"},{"id":"T51","span":{"begin":1658,"end":1663},"obj":"GeneOrGeneProduct"},{"id":"T52","span":{"begin":1673,"end":1682},"obj":"GeneOrGeneProduct"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin-Disease-MeSH
{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T1","span":{"begin":411,"end":423},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":1315,"end":1321},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"originalLabel","subj":"T1","obj":"D011086"},{"id":"A2","pred":"originalLabel","subj":"T2","obj":"D000740"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin-GeneOrGeneProduct-v3
{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T1","span":{"begin":12,"end":16},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":77,"end":87},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":182,"end":186},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":241,"end":246},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":334,"end":338},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":369,"end":373},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":429,"end":433},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":505,"end":509},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":596,"end":600},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":680,"end":684},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":779,"end":795},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":805,"end":809},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":811,"end":815},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":817,"end":821},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":823,"end":827},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":834,"end":839},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":844,"end":854},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":860,"end":864},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":905,"end":911},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":913,"end":917},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":919,"end":925},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":934,"end":938},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":940,"end":946},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":954,"end":962},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":1069,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":1080,"end":1085},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":1095,"end":1101},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":1103,"end":1109},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":1114,"end":1118},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":1169,"end":1174},"obj":"GeneOrGeneProduct"},{"id":"T31","span":{"begin":1237,"end":1241},"obj":"GeneOrGeneProduct"},{"id":"T32","span":{"begin":1242,"end":1246},"obj":"GeneOrGeneProduct"},{"id":"T33","span":{"begin":1247,"end":1252},"obj":"GeneOrGeneProduct"},{"id":"T34","span":{"begin":1353,"end":1365},"obj":"GeneOrGeneProduct"},{"id":"T35","span":{"begin":1366,"end":1376},"obj":"GeneOrGeneProduct"},{"id":"T36","span":{"begin":1424,"end":1434},"obj":"GeneOrGeneProduct"},{"id":"T37","span":{"begin":1547,"end":1551},"obj":"GeneOrGeneProduct"},{"id":"T38","span":{"begin":1631,"end":1641},"obj":"GeneOrGeneProduct"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin_Mondo_095
{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":411,"end":423},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":963,"end":965},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":1315,"end":1321},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0005571"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0010631"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0002280"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin-MeSH-Disease-2
{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":411,"end":423},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":1315,"end":1321},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"D011086"},{"id":"A2","pred":"ID:","subj":"T2","obj":"D000740"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin-MONDO_bioort2019
{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":411,"end":423},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":1315,"end":1321},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"#label","subj":"T1","obj":"D011086"},{"id":"A2","pred":"#label","subj":"T2","obj":"D000740"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin-Chemical-MeSH-CHEBI
{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T1","span":{"begin":111,"end":114},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":178,"end":181},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":501,"end":504},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":592,"end":595},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":676,"end":679},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":765,"end":768},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":856,"end":859},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":969,"end":972},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":1124,"end":1127},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":1405,"end":1408},"obj":"ChemicalEntity"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A2","pred":"ID:","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A3","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A4","pred":"ID:","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A5","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A6","pred":"ID:","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A7","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A8","pred":"ID:","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A9","pred":"ID:","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A10","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
LitCoin-training-merged
{"project":"LitCoin-training-merged","denotations":[{"id":"T10","span":{"begin":1405,"end":1408},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":1124,"end":1127},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":969,"end":972},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":856,"end":859},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":765,"end":768},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":676,"end":679},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":592,"end":595},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":501,"end":504},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":178,"end":181},"obj":"ChemicalEntity"},{"id":"T1","span":{"begin":111,"end":114},"obj":"ChemicalEntity"},{"id":"T38","span":{"begin":1631,"end":1641},"obj":"GeneOrGeneProduct"},{"id":"T37","span":{"begin":1547,"end":1551},"obj":"GeneOrGeneProduct"},{"id":"T36","span":{"begin":1424,"end":1434},"obj":"GeneOrGeneProduct"},{"id":"T35","span":{"begin":1366,"end":1376},"obj":"GeneOrGeneProduct"},{"id":"T34","span":{"begin":1353,"end":1365},"obj":"GeneOrGeneProduct"},{"id":"T33","span":{"begin":1247,"end":1252},"obj":"GeneOrGeneProduct"},{"id":"T32","span":{"begin":1242,"end":1246},"obj":"GeneOrGeneProduct"},{"id":"T31","span":{"begin":1237,"end":1241},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":1169,"end":1174},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":1114,"end":1118},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":1103,"end":1109},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":1095,"end":1101},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":1080,"end":1085},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":1069,"end":1074},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":954,"end":962},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":940,"end":946},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":934,"end":938},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":919,"end":925},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":913,"end":917},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":905,"end":911},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":860,"end":864},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":844,"end":854},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":834,"end":839},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":823,"end":827},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":817,"end":821},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":811,"end":815},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":805,"end":809},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":779,"end":795},"obj":"GeneOrGeneProduct"},{"id":"T97064","span":{"begin":680,"end":684},"obj":"GeneOrGeneProduct"},{"id":"T54613","span":{"begin":596,"end":600},"obj":"GeneOrGeneProduct"},{"id":"T65866","span":{"begin":505,"end":509},"obj":"GeneOrGeneProduct"},{"id":"T28563","span":{"begin":429,"end":433},"obj":"GeneOrGeneProduct"},{"id":"T27717","span":{"begin":369,"end":373},"obj":"GeneOrGeneProduct"},{"id":"T38822","span":{"begin":334,"end":338},"obj":"GeneOrGeneProduct"},{"id":"T8192","span":{"begin":241,"end":246},"obj":"GeneOrGeneProduct"},{"id":"T21007","span":{"begin":182,"end":186},"obj":"GeneOrGeneProduct"},{"id":"T36952","span":{"begin":77,"end":87},"obj":"GeneOrGeneProduct"},{"id":"T44540","span":{"begin":12,"end":16},"obj":"GeneOrGeneProduct"},{"id":"T86264","span":{"begin":1315,"end":1321},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T91349","span":{"begin":411,"end":423},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A4","pred":"ID:","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A8","pred":"ID:","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A10","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A2","pred":"ID:","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A57642","pred":"#label","subj":"T91349","obj":"D011086"},{"id":"A43667","pred":"#label","subj":"T86264","obj":"D000740"},{"id":"A9","pred":"ID:","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A5","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A6","pred":"ID:","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A7","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"},{"id":"A3","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_81579"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}
PubmedHPO
{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":411,"end":423},"obj":"HP_0001901"},{"id":"T2","span":{"begin":1315,"end":1321},"obj":"HP_0001903"}],"text":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.\nCertain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis. To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors. Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold. A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g. EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1. EPO regulation of signal transduction factors was also interestingly complex. For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components. Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia). Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated \u003e5-fold by EPO. Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation. The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation."}